---
title: "Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Clinical evidence"
description: "Formulary evidence on Anaphylm (dibutepinephrine, AQST-109) in Type I allergic reactions including anaphylaxis: Clinical evidence. Covers AQ109301, OASIS, AQ109109, Anaphylm human factors validation study, PARKS, EPIPHAST II, and 4 further headings. 166 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/clinical-evidence"
published: "2026-09-21T21:39:21-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 AQ109301

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Comparison of single and repeat doses of AQST-109 with intramuscular epinephrine

> “To compare the pharmacokinetics (PK) and pharmacodynamics (PD) of single dose and repeat doses (RD) of AQST-109 with intramuscular epinephrine in healthy adults.”

Source: [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/)

<a id="topic-3.1.1.1-2"></a>

###### Primary and secondary objectives stated at study initiation

> “The primary objective is to compare the PK of epinephrine following the single administration of Anaphylm to single administration of epinephrine IM injection in healthy adult subjects. The secondary objectives include evaluating PK sustainability following repeat administration and evaluating the safety and tolerability following single and repeat administrations versus epinephrine IM injection and epinephrine autoinjectors.”

Source: [Aquestive Therapeutics phase 3 first participant dosed (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-doses-first-patient-phase-3-pivotal)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Single-center study with first participant dosed in December 2023

> “The two-part, Phase 3, single-center, open-label, randomized study is designed to compare the PK and pharmacodynamics (PD) of single and repeat doses of Anaphylm versus single and repeat doses of the epinephrine IM injection and epinephrine autoinjectors (EpiPen® and Auvi-Q®) in healthy adult subjects.”

Source: [Aquestive Therapeutics phase 3 first participant dosed (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-doses-first-patient-phase-3-pivotal)

<a id="topic-3.1.1.2-2"></a>

###### Topline data reported in March 2024

> “today released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film and findings from the FDA Type C meeting.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Two-part open-label crossover design with injectable comparators

> “In this 2-part, phase 3, open-label study, participants received single dose and RD of AQST-109 and epinephrine via manual syringe, EpiPen, or Auvi-Q autoinjector on different days.”

Source: [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/)

<a id="topic-3.1.1.3-2"></a>

###### Structure of Part A and Part B

> “Part A of the two-part Phase 3 is designed as a three-period, three-treatment, six sequence, comparative PK study and is expected to enroll up to 36 subjects.”
> “Part B is designed as a four-period, four-treatment, four-sequence, comparative PK study and is expected to enroll up to 64 subjects, inclusive of those who participated in Part A.”

Source: [Aquestive Therapeutics phase 3 first participant dosed (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-doses-first-patient-phase-3-pivotal)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Healthy adult participants

> “The two-part, Phase 3, single-center, open-label, randomized study was designed to compare the PK and pharmacodynamics (PD) of single and repeat doses of Anaphylm versus single and repeat doses of the epinephrine intra-muscular (IM) injection and epinephrine autoinjectors (EpiPen® and Auvi-Q®) in healthy adult subjects.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Anaphylm 12 mg with bracketing autoinjector and manual intramuscular comparators

> “Part A will assess both the PK performance and sustainability of Anaphylm 12mg with the bracketed comparison of an epinephrine autoinjector (EpiPen) and epinephrine manual IM injection.”
> “Part B will assess the PK of a single dose of Anaphylm 12mg with the bracketed comparison of two autoinjectors (EpiPen and Auvi-Q) and the manual IM injection.”

Source: [Aquestive Therapeutics phase 3 first participant dosed (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-doses-first-patient-phase-3-pivotal)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Bracketed Epinephrine Exposure as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Regulatory basis for bracketing exposure against approved injectable products

> “As expected, the FDA reiterated that, as with other epinephrine programs under development, concentrations of epinephrine above known EpiPen levels must be justified from a safety perspective, and PK sustainability remains a focus.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="topic-3.1.1.6.1-2"></a>

###### Bracketing of approved intramuscular products in earlier phase 1 work

> “AQST-109 delivered epinephrine with PK and PD results within the bracketed range of approved intramuscular products.”

Source: [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/)

<a id="topic-3.1.1.6.1-3"></a>

###### Endpoint measures and sampling window

> “PK and PD parameters were assessed in 360 minutes post-administration; primary end points were maximum serum concentration and partial area under the curve. Additional PK and PD end points including blood pressure and heart rate were also measured.”

Source: [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/)

<a id="topic-3.1.1.6.1-4"></a>

###### Primary and secondary endpoints as reported with topline data

> “The primary endpoint was to compare the PK of epinephrine following the single administration of Anaphylm to the single administration of Adrenalin (epinephrine IM injection) and autoinjectors in healthy adult subjects. The secondary endpoints included evaluating PK sustainability following repeat administration and the safety and tolerability following single and repeat administrations versus epinephrine IM injection and epinephrine autoinjectors.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Participants enrolled in the single-dose and repeat-dose parts

> “The single dose part of the Phase 3 study was designed as a four-period, four-treatment, four-sequence, comparative PK study with 64 enrolled adult subjects.”
> “The repeat dosing part of the Phase 3 study was designed as a three-period, three-treatment, six sequence, comparative PK study with 36 enrolled adult subjects.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Single-dose pharmacokinetics and pharmacodynamics

> “Achieved a geometric mean Cmax of 470 pg/mL bracketed by epinephrine autoinjectors AUVI-Q at 521 pg/mL and EpiPen at 469 pg/mL,”
> “Generated partial AUCs between (bracketed) autoinjectors and Adrenalin manual IM injection from 5 to 60 minutes”
> “Maintained a median Tmax of 12 minutes compared to 20 minutes for EpiPen, 30 minutes for AUVI-Q, and 50 minutes for Adrenalin,”
> “Produced a meaningful change from baseline pharmacodynamic measures of blood pressure and heart rate at the first tracked time point of 2 minutes, and”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="topic-3.1.1.8.3-2"></a>

###### Repeat-dose pharmacokinetics and pharmacodynamics

> “Maintains epinephrine plasma concentrations equal to or greater than existing injection products at all but 1 timepoint out to 2 hours,”
> “Demonstrated a median Tmax of 10 minutes after administration of the second dose,”
> “Exhibited consistent pharmacodynamics, and”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="topic-3.1.1.8.3-3"></a>

###### Published single-dose and repeat-dose results

> “After single dose AQST-109 administration, area under the curve and maximum serum concentration met the primary end point of PK bracketing of 60 minutes, exceeding that of manual intramuscular injection, equaling EpiPen, but lower than that of Auvi-Q.”
> “AQST-109 had a median time-to-maximum plasma concentration of 12 minutes, exceeding that of EpiPen (20 minutes), Auvi-Q (30 minutes), and intramuscular injection (50 minutes); there was also more consistency (narrower IQR) than the comparators.”
> “AQST-109 demonstrated more rapid and larger increases in blood pressure and heart rate than the comparators. RD AQST-109 had greater than dose-proportional increases in PK and PD parameters, exceeding the comparators.”

Source: [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### No serious adverse events in either part of the study

> “Was consistently well tolerated with no SAEs.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="topic-3.1.1.8.5-2"></a>

###### Safety outcome reported in the publication

> “No serious adverse events were reported.”

Source: [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: study limitations

The study enrolled healthy adult volunteers rather than participants experiencing an allergic reaction, so epinephrine exposure and hemodynamic response were measured under conditions that differ from an anaphylaxis emergency. It was open label and single center, no clinical efficacy endpoint such as symptom reversal was assessed, and the comparison with approved injectable products rested on pharmacokinetic bracketing rather than on a direct clinical outcome. Enrollment totalled 64 participants in the single-dose part and 36 in the repeat-dose part, and no registry record identifying the trial on ClinicalTrials.gov was located.

Source: [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/); [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm); [Aquestive Therapeutics phase 3 first participant dosed (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-doses-first-patient-phase-3-pivotal)

<a id="heading-3.1.2"></a>

#### 3.1.2 OASIS

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Effect of oral allergen challenge on absorption

> “To compare AQST-109's PK and PD in adults with oral allergy syndrome undergoing oral allergen challenge (OAC) to elicit symptoms.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="topic-3.1.2.1-2"></a>

###### Comparison of single and repeat doses with and without allergen challenge

> “A 2-part open-label study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as single and repeat doses of DESF in healthy adults with oral allergy syndrome (OAS).”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Single United States site and study dates

| Field | Quoted record |
| --- | --- |
| Location | “Secaucus, New Jersey, United States, 07094” |
| Facility | “Frontage Clinical Services, Inc.” |
| Study start (actual) | “2024-07-17” |
| Primary completion (actual) | “2024-10-10” |
| Study completion (actual) | “2024-10-13” |

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Two-part fixed-sequence stratified crossover design

> “This was a phase 2, 2-part, open-label, randomized, fixed-sequence, stratified, crossover study to evaluate the PK and PD of single (12 mg) and repeat doses (12 mg × 2) of AQST-109 in adults with screening-confirmed oral allergy syndrome administered with and without OAC, and of single (0.3 mg) and repeat doses (0.3 mg × 2) of manual intramuscular epinephrine injection given without OAC.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="topic-3.1.2.3-2"></a>

###### Oromucosal allergen challenge procedure

> “Allergen Challenge: The oromucosal allergen challenge begins approximately 20 minutes before the expected administration of DESF. Subjects have a single food allergen known to trigger an allergic reaction in the subject placed on their tongue for up to 15 minutes after initial exposure to upper and lower lips and gums. Subjects keep the allergen in place for up to 15 minutes until symptoms are reported. The subjects are monitored from the start of the allergen challenge to determine severity of symptoms. The allergen is then removed from the mouth and within 5 minutes subjects rate their symptoms and DESF is administered.”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="topic-3.1.2.3-3"></a>

###### Treatment periods in Part 1 and Part 2

> “In Part 1, there are three treatment periods evaluating single and repeat doses of study drug, DESF after an allergen challenge (Treatment Period 1), intramuscular (IM) injection without allergen challenge (Treatment Period 2), and DESF without allergen challenge (Treatment Period 3). In Part 2, there are two treatment periods evaluating single and repeat doses of study drug, DESF after an allergen challenge (Treatment Period 1) and intramuscular (IM) injection without allergen challenge (Treatment Period 2).”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria

> “Healthy males and females 18 through 55 years of age.”
> “Known history of oral allergy syndrome in response to exposure to any of the allergens (e.g., apple, cherry, mango, melon, kiwi, celery, banana and/or carrot).”
> “Subject has not had exposure to antihistamines within 3 days prior to the Screening visit.”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria relating to the oral mucosa

> “Known history or presence of any disorder of the sublingual mucosa or any disease or condition which affects the normal production of saliva (e.g., xerostomia, Ehlers-Danlos syndrome, or Sjögren's syndrome) which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Single-dose cohort

> “Single dose of DESF (12 mg) administered after allergen challenge (Treatment Period 1), followed by a single dose of intramuscular (IM) manual injection (0.3 mg) without allergen challenge after a 24-hour washout period (Treatment Period 2), followed by a single dose of DESF (12 mg) without allergen challenge after a 14-day washout period from Treatment Period 1.”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="topic-3.1.2.5-2"></a>

###### Repeat-dose cohort

> “Repeat dose of DESF (24 mg [12 mg x 2]) administered after allergen challenge (Treatment Period 1), followed by a repeat dose of IM manual injection (0.6 mg [0.3 mg x 2]) without allergen challenge after a 24-hour washout period (Treatment Period 2), followed by a repeat dose of DESF (24 mg [12 mg x 2]) without allergen challenge after a 14-day washout period from Treatment Period 1.”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="topic-3.1.2.5-3"></a>

###### Sublingual administration and intramuscular comparator

> “DESF administered in the sublingual space.”
> “Epinephrine manual injection administered intramuscularly according to the approved prescribing information.”

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Baseline-corrected Maximum Epinephrine Plasma Concentration as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registered primary outcome measures

| Outcome measure | Quoted description | Quoted time frame |
| --- | --- | --- |
| Cmax | “Baseline Corrected Maximum Epinephrine Plasma Concentration occurring at Tmax (Time to reach maximum concentration)” | “0 to 240 minutes post-dose” |
| AUC0-10 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 10 minutes” | “0 to 10 minutes” |
| AUC0-20 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 20 minutes” | “0 to 20 minutes” |
| AUC0-30 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 30 minutes” | “0 to 30 minutes” |
| AUC0-45 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 45 minutes” | “0 to 45 minutes” |

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="topic-3.1.2.6.1-2"></a>

###### Rationale for testing absorption under allergen-induced oral change

> “AQST-109 is an investigational epinephrine prodrug sublingual film for anaphylaxis treatment, with well-characterized pharmacokinetics (PK) and pharmacodynamics (PD) in healthy adults. It is unclear how oral symptoms during allergic reactions may affect its absorption and these parameters.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="topic-3.1.2.6.1-3"></a>

###### Regulatory request that prompted the allergen challenge design

> “Regarding mouth conditions, the FDA recommended administering Anaphylm after oral exposure to a known allergen and assessing PK performance thereunder. The Company will execute this study in the second quarter of 2024. This study will replace the Company’s previously planned angioedema study.”

Source: [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned and actual enrollment

| Field | Quoted record |
| --- | --- |
| Planned enrollment, Part 1 | “Up to 36 subjects will be enrolled in Part 1.” |
| Planned continuation into Part 2 | “Up to 12 subjects who have completed Part 1 (6 from each cohort) may continue to Part 2.” |
| Enrollment (actual) | “36” |

Source: [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Pharmacokinetic, pharmacodynamic, and safety subsets

> “Geometric means for PK and PD parameters were analyzed for the PK, PD, and safety subsets.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participants per arm in Part 1 and crossover in Part 2

> “Part 1 of the study enrolled subjects with confirmed OAS into a three-period study with the following arms: (1) Anaphylm with allergen exposure (n=18 single dose; n=18 repeat dose); (2) Anaphylm without allergen exposure (n=15 single dose; n=13 repeat dose); and (3) Adrenalin intramuscular (IM) injection without allergen exposure (n=18 single dose; n=17 repeat dose). Part 2 was an optional follow-on study to Part 1. Six subjects who received single dose in Part 1 received repeat dose; and six subjects who received repeat dose in Part 1 received single dose.”

Source: [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Severity of allergen-induced oral symptoms at screening

> “During screening with OAC, 94.4% of the 36 patients experienced moderate or severe oral symptoms.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="topic-3.1.2.8.2-2"></a>

###### Distribution of symptoms after allergen exposure

> “Following allergen exposure, all subjects reported symptoms consistent with those experienced with their known allergies. Approximately twenty-five percent of subjects reported swelling of their tongues, lips, cheeks, and/or throat. Additional mucosal allergic symptoms included tingling, pain, and nasal congestion. Ninety-four percent of subjects were categorized as having moderate or severe symptoms according to the pre-defined oral severity score.”

Source: [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Pharmacokinetics and pharmacodynamics with and without allergen challenge

> “Pharmacodynamics were not impacted by OAC after single- and repeat-dose administration of AQST-109 vs without OAC. AQST-109 PK values were similar with or without OAC. Single- and repeat-dosing PD parameters were higher with AQST-109 after OAC vs intramuscular epinephrine injection without OAC, and were nonsignificantly higher for AQST-109 with vs without OAC.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="topic-3.1.2.8.3-2"></a>

###### Endpoints met and time to maximum concentration

> “Both primary and secondary endpoints of the OAS challenge study were successfully met with no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. Anaphylm PK results in subjects with allergen exposure remained similar to previous profiles from the Company’s pivotal study in healthy subjects. The time to maximum plasma concentration, or Tmax, remained at twelve minutes in subjects with and without allergen exposure following a single dose of Anaphylm.”

Source: [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="topic-3.1.2.8.3-3"></a>

###### Time to resolution of allergen-induced oral symptoms

> “The median time for complete symptom resolution for subjects in the study following administration of Anaphylm was twelve minutes. This is faster than the median time to complete symptom resolution at screening, which was seventy-four minutes. After Anaphylm administration, symptoms began resolving as early as two minutes in some subjects and fifty percent of all symptoms across all subjects were resolved by five minutes. Importantly, all instances of symptomatic swelling were completely resolved by five minutes after administration of Anaphylm.”

Source: [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="topic-3.1.2.8.3-4"></a>

###### Conclusion on absorption during oral allergic symptoms

> “AQST-109 PK and PD are not diminished with oral symptoms and changes, supporting reliable absorption in allergic reactions in such contexts.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Participant-rated oral symptoms after allergen exposure

> “During allergen exposure arms in Parts 1 and 2, subjects were exposed to a fruit they were known to be allergic to, and the resulting symptoms were documented for location, severity, and duration. There were no reports of difficulty administering Anaphylm to subjects in the study.”

Source: [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Treatment-emergent adverse events

> “Almost all patients experienced a related mild treatment-emergent adverse event; 4 were considered moderate in severity, and no new safety signals were identified compared with previous studies.”

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)

<a id="topic-3.1.2.8.5-2"></a>

###### Tolerability reported with topline data

> “In addition, Anaphylm was safe and well-tolerated with all adverse events categorized as mild or moderate and resolving without medical intervention.”

Source: [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: study limitations

The study enrolled 36 adults with oral allergy syndrome at a single site and used a fruit allergen challenge to produce oral symptoms, a model of localized oral change rather than of systemic anaphylaxis. The design was open label and fixed sequence, the intramuscular comparator was given without allergen challenge, and Part 2 involved only 12 participants who crossed between single and repeat dosing. Symptom resolution was recorded after epinephrine administration without a placebo or no-treatment control, so the contribution of spontaneous resolution cannot be separated from the treatment effect.

Source: [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/); [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937); [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)

<a id="heading-3.1.3"></a>

#### 3.1.3 AQ109109

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Confirmatory pharmacokinetic study requested in the Complete Response Letter

> “The FDA issued a Complete Response Letter (CRL) on January 30, 2026, which requested that the Company complete a human factors study addressing packaging and administration, and a confirmatory pharmacokinetic (PK) study of Anaphylm.”

Source: [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)

<a id="topic-3.1.3.1-2"></a>

###### Comparison of self-administration, clinician administration, and manual intramuscular injection

> “In addition, using the revised packaging and revised instructions for use, the Company conducted a single PK study in healthy volunteers comparing self-administration to clinician-administered as well as manual intramuscular (IM) administration.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Topline results reported in August 2026

> “08.10.26 at 7:00 AM EDT”
> “today announced results from its human factors (HF) validation study and pharmacokinetic (PK) study for Anaphylm™ (dibutepinephrine) sublingual film, conducted in support of the Company’s planned resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of Type 1 allergic reactions, including anaphylaxis.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Study arms, including a purposely misplaced administration arm

> “The FDA also requested that Aquestive include a PK arm studying purposely misplaced administration of Anaphylm on top of the tongue or on the roof of the mouth, intended to demonstrate the impact of incorrect placement on PK and PD measures and tolerability.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.3.3-2"></a>

###### Alignment with the FDA on the design before conduct

> “Aquestive provided the proposed PK study design to the FDA prior to the Type A meeting and received preliminary comments in advance of the meeting. Most of the preliminary comments provided by the FDA were focused on ensuring consistency between past PK studies conducted by the Company and the proposed current design.”

Source: [Aquestive Therapeutics Type A meeting completion (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-completion-type-meeting-fda)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Healthy volunteers

> “Table 1: Clinical PK Study in Healthy Subjects Comparing Anaphylm Self-Administration to Clinician-Administered and Epinephrine IM Administration (Study AQ109109)*”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Revised packaging and instructions for use with an intramuscular comparator

> “The Company also completed a confirmatory PK study in healthy volunteers using the revised packaging and revised instructions for use, which evaluated self-administration and clinician administration of Anaphylm and included manual intramuscular epinephrine as a comparator.”

Source: [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Geometric Mean Cmax and Median Tmax as the Primary Endpoints

<a id="topic-3.1.3.6.1-1"></a>

###### Comparison of self-administered with clinician-administered exposure

> “Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK results”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.3.6.1-2"></a>

###### Pharmacodynamic assessment of incorrect film placement

> “Top-of-tongue PK arm showed clinically meaningful pharmacodynamic (PD) results”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### No administration errors in the self-administration arm

> “No administration errors were observed in the self-administration arm of the PK study.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.3.8.1-2"></a>

###### Use errors reported at resubmission

> “No protocol-defined use errors were observed in the self-administration arm of the PK study.”

Source: [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Pharmacokinetic results by administration route

| Description | Anaphylm self-administered | Anaphylm clinician-administered | Manual IM clinician-administered |
| --- | --- | --- | --- |
| Geometric mean Cmax (pg/mL) | “391.7” | “357.6” | “334.5” |
| Median Tmax (minutes) | “12” | “12” | “45” |

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.3.8.3-2"></a>

###### Pharmacokinetics and pharmacodynamics after top-of-tongue placement

> “As expected, compared with prior clinical studies where the film was administered as per the instructions, the geometric mean Cmax is significantly lower and the Tmax significantly longer than with correct placement of our sublingual film. However, top-of-tongue placement resulted in a geometric mean Cmax above 100 pg/mL (baseline unadjusted), a median Tmax of 35 minutes, and clinically meaningful PD results that were comparable to or of greater magnitude than those observed with injectable epinephrine.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Adverse events and film retention

> “From a tolerability perspective, there were no participants in the HF study and no subjects in the PK study who prematurely removed the film. In the PK study there were no serious adverse events, no serious events, and no events that led to study drug discontinuation.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: study limitations

Results are available only from a company topline announcement and a regulatory update, so the number of participants, the analysis sets, the statistical methods, and the confidence intervals around the reported geometric mean Cmax and median Tmax values have not been reported. The study was conducted in healthy volunteers rather than during allergic reactions, and the pharmacodynamic comparison for the top-of-tongue arm was described as a cross-study comparison against results from study AQ109301 rather than a within-study randomized comparison. No peer-reviewed publication or registry record for the study was located.

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors); [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)

<a id="heading-3.1.4"></a>

#### 3.1.4 Anaphylm Human Factors Validation Study

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Evaluation of a revised packaging design and instructions for use

> “The new HF study evaluated a revised packaging design, incorporating modifications to the pouch opening, instructions for use, and pouch and carton labeling intended to address previously identified issues.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.4.1-2"></a>

###### Use-related deficiencies identified by the FDA that the study addressed

> “Specifically, the Company received a Complete Response Letter (CRL) from the FDA in January 2026 which indicated that, in a previous human factors study, participants had difficulty opening the pouch, tore the film during pouch opening, incorrectly placed the film during administration, chewed the film, and/or removed the film after administration.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Topline results reported in August 2026

> “Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### User groups and protocol agreed with the FDA

> “The FDA recommended changes to the user groups to be included in the HF study design and, after discussion at the Type A meeting, the Company believes there is general alignment with the FDA on key HF study elements. Aquestive plans to submit the HF study protocol for FDA review, as recommended by the FDA.”

Source: [Aquestive Therapeutics Type A meeting completion (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-completion-type-meeting-fda)

<a id="topic-3.1.4.3-2"></a>

###### Container closure revisions tested in the study

> “During the meeting, the Company shared with the FDA the revisions made to the opening mechanisms of the product container closure, which were designed to provide improvements in the ability to open the pouch while also mitigating the potential tearing of the film. The FDA acknowledged the changes made to the Anaphylm container closure, which will be tested in the Company’s upcoming HF study.”

Source: [Aquestive Therapeutics Type A meeting completion (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-completion-type-meeting-fda)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Revised packaging, instructions for use, and labeling

> “In response to the CRL, Aquestive completed a human factors study evaluating revised packaging that incorporated modifications to the pouch opening, instructions for use, and pouch and carton labeling.”

Source: [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Observed Use Errors as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Use errors mapped to the deficiencies named in the Complete Response Letter

> “The new HF study shows significant improvement across each deficiency identified by the FDA.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.4.6.1-2"></a>

###### Pouch-opening time and film placement as reported endpoints

> “Revised packaging design reduced median time to open pouch from 17 seconds in the previous human factors study to 3 seconds”
> “Revised instructions for use reduced incorrect film placement from previous human factors validation study by over 80%”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Participants in the previous and the revised human factors studies

> “The number of participants who had difficulty opening the pouch decreased from 26 (out of 166) to 1 (out of 105).”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Use errors observed with the revised packaging and instructions for use

> “The median time to open a pouch decreased from 17 seconds in the previous study to 3 seconds. The number of participants who had difficulty opening the pouch decreased from 26 (out of 166) to 1 (out of 105). The number of participants who incorrectly administered the film in the mouth decreased from 20 (out of 166) to 2 (out of 105). In the latest HF study, no participants were observed chewing the film or removing the film.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="topic-3.1.4.8.3-2"></a>

###### Pouch-opening time reported at resubmission

> “The completed studies generated human factors, pharmacokinetic, and pharmacodynamic data supporting the revised packaging design and instructions for use, including reducing median pouch-opening time from 17 seconds to 3 seconds.”

Source: [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Film retention during the study

> “From a tolerability perspective, there were no participants in the HF study and no subjects in the PK study who prematurely removed the film.”

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: study limitations

The comparison of 105 participants in the revised study with 166 participants in the earlier study is a comparison across two separate human factors studies rather than a randomized within-study comparison, and the user groups differed after the FDA recommended changes to them. Simulated-use testing measures handling of the packaging under observation and does not establish behaviour during an actual allergic reaction. Only topline counts have been released, with no report of the full set of use errors, the task analysis, or the participant characteristics, and the results have not been published or registered.

Source: [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors); [Aquestive Therapeutics Type A meeting completion (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-completion-type-meeting-fda)

<a id="heading-3.1.5"></a>

#### 3.1.5 PARKS

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Pharmacokinetics, pharmacodynamics, safety, and tolerability in children and adolescents

> “An open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of epinephrine administered as a single dose of DESF in pediatric subjects weighing ≥30 kg with a personal history of allergic reactions and are at high risk for serious allergic reactions.”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study dates and number of sites

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2024-12-26” |
| Primary completion (actual) | “2025-03-14” |
| Study completion (actual) | “2025-05-21” |
| Number of locations | “This study has 8 locations” |

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="topic-3.1.5.2-2"></a>

###### Participating sites in the United States and Canada

> “AllerVie Clinical Research”
> “UCLA Pediatric Allergy & Immunology”
> “Children's Hospital Colorado”
> “Texas Children's Hospital - Feigin Center”
> “Halton Pediatric Allergy”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Single-treatment open-label design

> “This is a Phase 1, multi-site, open-label, single treatment study conducted in male and female pediatric subjects (age 7-17 years) who have a have a personal history of allergic reactions and are at high risk for serious allergic reactions. This study is designed to evaluate the pharmacokinetics (PK) of epinephrine administered as a single dose of DESF.”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="topic-3.1.5.3-2"></a>

###### Study schedule and duration

> “The expected maximum duration of an individual's participation in this study will be, approximately, 32 days including a 30-day Screening Period, a 1-day Treatment Period (Study Day 1) and a 1-day (±1 day) Post-treatment Follow-up (Study Day 2).”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Key inclusion criteria

> “Male and female children ages 7 through 17 years of age at the start of the Screening Period.”
> “Participants with a known history of allergic reactions with an active prescription for epinephrine, and who (in the judgement of the investigator) are at high risk for serious allergic reactions (e.g., anaphylaxis).”
> “Participant has a body weight ≥30 kg (66 lbs).”
> “Participant is within the 5th and 95th percentiles, inclusive, for weight by age (according to CDC growth charts).”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="topic-3.1.5.4-2"></a>

###### Key exclusion criteria

> “Any current or past medical conditions such as significant systemic diseases that, in the investigator's opinion, might significantly affect pharmacodynamic responses to DESF.”
> “Known intolerance or hypersensitivity to any component of DESF.”
> “Participant has a disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of DESF.”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single 12 mg sublingual dose

> “All treated participants will be administered a single, 12 mg, dose of DESF on Study Day 1. No other investigational product will be administered.”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="topic-3.1.5.5-2"></a>

###### Route of administration

> “DESF administered in the sublingual space”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Baseline-corrected Maximum Epinephrine Plasma Concentration as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registered primary outcome measures

| Outcome measure | Quoted description | Quoted time frame |
| --- | --- | --- |
| Cmax | “Baseline Corrected Maximum Epinephrine Plasma Concentration” | “0 to 240 minutes post-dose” |
| AUC0-10 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 10 minutes” | “0 to 10 minutes” |
| AUC0-20 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 20 minutes” | “0 to 20 minutes” |
| AUC0-30 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 30 minutes” | “0 to 30 minutes” |
| AUC0-45 | “Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 45 minutes” | “0 to 45 minutes” |

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="topic-3.1.5.6.1-2"></a>

###### Purpose of matching adult exposure to support pediatric labeling

> “These data are an important component of the FDA review process and could enable Anaphylm to have a label that includes this pediatric patient population.”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="topic-3.1.5.6.1-3"></a>

###### Oral mucosal tolerability assessment

> “On Study Day 2, participants will return to the study site for an Oral Mucositis Assessment Scale (OMAS) assessment.”

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned and actual enrollment

| Field | Quoted record |
| --- | --- |
| Planned enrollment | “Up to 24 DESF treated pediatric participants are expected to be enrolled.” |
| Enrollment (actual) | “32” |

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)

<a id="topic-3.1.5.7.1-2"></a>

###### Participants who completed the study

> “A total of thirty-two patients completed the study.”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Completion of the study

> “A total of thirty-two patients completed the study.”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Age and weight of the enrolled population

> “today announced positive topline results from its pediatric study for Anaphylm™ (epinephrine) sublingual film in patients aged seven to seventeen and weighing greater than thirty kilograms with a personal history of allergic reactions.”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Pharmacokinetic profile compared with adult studies

> “The pediatric study was a multi-site, single treatment study designed to evaluate the PK, pharmacodynamics (PD), safety, and tolerability of Anaphylm. A total of thirty-two patients completed the study. The PK results were consistent with previous adult studies.”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="topic-3.1.5.8.3-2"></a>

###### Comparison figure against the adult pivotal study

> “Geometric mean baseline adjusted epinephrine concentration over time after administration of Anaphylm 12mg in pediatric subjects (Study AQ109302) compared to adult subjects (Study AQ109301B)”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### No serious adverse events

> “Importantly, Anaphylm was shown to be safe and well-tolerated with no serious adverse events (SAEs) reported.”

Source: [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: study limitations

The study was open label, gave a single 12 mg dose with no comparator arm, and enrolled 32 participants aged 7 through 17 years who weighed at least 30 kg, so it provides no evidence for younger or lighter children, for whom 0.15 mg injectable products are used. Participants were dosed while well rather than during an allergic reaction. Results have been described only in a company announcement and the registry record carries no posted results, so individual pharmacokinetic parameters, variability, and the Oral Mucositis Assessment Scale findings are not publicly reported.

Source: [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982); [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)

<a id="heading-3.1.6"></a>

#### 3.1.6 EPIPHAST II

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Comparison of single and repeat doses with EpiPen and manual intramuscular epinephrine

> “The EPIPHAST II trial was designed to compare single doses of AQST-109 to EpiPen® 0.3mg and epinephrine 0.3mg intramuscular (IM) injection, as well as repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection.”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Topline results reported in September 2022

> “WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film.”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Randomized open-label crossover phase 1 design

> “Data were integrated from 2 randomized, open-label, phase I crossover trials that evaluated the PK and PD of epinephrine in 54 healthy volunteers.”

Source: [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/)

<a id="topic-3.1.6.3-2"></a>

###### Single-dose and repeat-dose comparisons

> “Aquestive is conducting its EPIHPHAST II study comparing AQST-109 to epi 0.3mg IM injection (repeat dose) and AQST-109 to EpiPen 0.3mg (single dose).”

Source: [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Healthy volunteers without other medical conditions

> “They had no previous medical conditions and were delivered either AQST-109 12 mg or 0.3 mg EpiPen, 0.3 mg generic EpiPen, 0.3 mg Auvi-Q, and 0.3 mg manual intramuscular injection.”

Source: [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### AQST-109 12 mg, EpiPen 0.3 mg, and epinephrine 0.3 mg intramuscular injection

> “The EPIPHAST II trial was designed to compare single doses of AQST-109 to EpiPen® 0.3mg and epinephrine 0.3mg intramuscular (IM) injection, as well as repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection.”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Time to Maximum Epinephrine Concentration as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Clinical importance of rapid systemic epinephrine delivery

> “Speed matters in delivering systemic epinephrine during an anaphylaxis event. Any delay can result in severe bronchospasm, acute respiratory failure and/or cardiovascular collapse, as well as less favorable outcomes and death”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="topic-3.1.6.6.1-2"></a>

###### Pharmacodynamic measures assessed alongside pharmacokinetics

> “After one dose of AQST-109, maximum mean effects on systolic blood pressure occurred within 5 minutes of dosing compared to 8 minutes for EpiPen. Maximum mean effects in heart rate occurred within 8 minutes of administering AQST-109 compared to an average of 5 minutes within administering EpiPen.”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Participants across the two integrated phase 1 trials

> “Data were integrated from 2 randomized, open-label, phase I crossover trials that evaluated the PK and PD of epinephrine in 54 healthy volunteers.”

Source: [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Time to maximum concentration after a single dose

> “Results from the single dose administration showed AQST-109 achieved a significantly faster Tmax (12 minutes), compared to both EpiPen® (22.5 minutes) and epinephrine 0.3mg IM injection (45 minutes).”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="topic-3.1.6.8.3-2"></a>

###### Maximum concentration after single and repeat dosing

> “AQST-109 repeat dosing provided significantly higher drug plasma concentrations, with a Tmax of 8 minutes after administration, and extensive absorption was observed. The mean maximum concentration (Cmax) of AQST-109 was 465 pg/mL after one dose and 2,958 pg/mL after two doses. In comparison, the epi 0.3mg IM injection Cmax was 489 pg/mL after one dose and 911 pg/mL after two doses. The single dose of EpiPen resulted in a Cmax of 869 pg/mL.”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

Additional sources: [Aquestive Therapeutics AAAAI poster presentations (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-present-positive-data-pharmacokinetic-and)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### No severe or serious adverse events

> “Safety results for AQST-109 were in line with expectations, and no severe or serious adverse events were reported.”

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary: study limitations

The trial was open label and enrolled healthy volunteers, so results describe epinephrine absorption and hemodynamic change in the absence of an allergic reaction. Reported results come from a company announcement and from an integrated analysis that pooled this trial with the earlier EPIPHAST trial, and the individual trial has no registry record and no separate peer-reviewed publication, so the number of participants, the analysis sets, and the variability around the reported Cmax and Tmax values are not available. Repeat dosing produced a mean Cmax of 2,958 pg/mL, well above the 911 pg/mL reported after two intramuscular doses, an exposure difference the FDA later required be justified on safety grounds.

Source: [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html); [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/); [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)

<a id="heading-3.1.7"></a>

#### 3.1.7 EPIPHAST

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Comparison of sublingual film with intramuscular epinephrine and selection of the final configuration

> “The EPIPHAST study is a randomized, open-label, three-part adaptive design, crossover study intended to compare the pharmacokinetics and pharmacodynamics of epinephrine following administration of AQST-109 and epinephrine administered as intramuscular injection in healthy adult subjects. This study will be used to determine the final product configuration that will be used to manufacture registration batches and conduct pivotal studies planned for the second half of 2022.”

Source: [Aquestive Therapeutics pre-IND response (2021)](https://www.globenewswire.com/news-release/2021/12/13/2350753/0/en/Aquestive-Therapeutics-Receives-Written-Response-to-Pre-IND-Submission-for-AQST-109-epinephrine-prodrug-sublingual-film-and-Begins-Recruitment-for-its-Epinephrine-Film-Pharmacokine.html)

<a id="topic-3.1.7.1-2"></a>

###### Purpose of Part 3

> “The purpose of Part 3 was to continue to study the administration of the film under a variety of conditions to further characterize its pharmacokinetics, pharmacodynamics, and safety.”

Source: [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Conducted in Canada under Health Canada clearance from late 2021

> “In addition, Health Canada has provided clearance for Aquestive’s crossover study, known as the EPIPHAST study, of AQST-109. Patient recruitment has begun and the Company expects the first dosing to occur before the end of the year.”

Source: [Aquestive Therapeutics pre-IND response (2021)](https://www.globenewswire.com/news-release/2021/12/13/2350753/0/en/Aquestive-Therapeutics-Receives-Written-Response-to-Pre-IND-Submission-for-AQST-109-epinephrine-prodrug-sublingual-film-and-Begins-Recruitment-for-its-Epinephrine-Film-Pharmacokine.html)

<a id="topic-3.1.7.2-2"></a>

###### Part-by-part reporting through 2022

> “WARREN, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from Part 1 of the EPIPHAST study for its AQST-109 epinephrine oral film.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Three-part adaptive crossover design

> “EPIPHAST is a randomized, open-label, three-part adaptive design, crossover study in healthy adult subjects comparing the pharmacokinetics and pharmacodynamics of epinephrine delivered via Aquestive’s AQST-109 oral film compared to intramuscular injection of epinephrine. The study is being conducted pursuant to clearance from Health Canada.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="topic-3.1.7.3-2"></a>

###### Part 2 replicate crossover design

> “Part 2 of the EPIPHAST study was a replicate design crossover study in twenty-four (24) healthy subjects comparing the pharmacokinetic and pharmacodynamic measures of AQST-109 12 mg and epinephrine intramuscular injection 0.3 mg.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="topic-3.1.7.3-3"></a>

###### Five administration-condition arms in Part 3

> “The first three arms were designed to assess the impact of holding the film under the tongue and limiting swallowing for different periods of time. These time periods were (1) the target holding time of 4 minutes, (2) a 50% reduction in hold time to 2 minutes and (3) no hold time, or 0 minutes. The remaining two arms of the study for which data are not yet available include (4) dosing the film 2 minutes after eating a peanut butter sandwich and (5) swallowing the film immediately with 240 mL of water.”

Source: [Aquestive Therapeutics EPIPHAST Part 3 initial results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000162828022017268/aqstepiphastpart3-arm1xt.htm)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Healthy adult volunteers

> “EPIPHAST was a randomized, open-label, three-part adaptive design, crossover study in healthy adult subjects comparing the pharmacokinetics and pharmacodynamics of epinephrine delivered via Aquestive’s AQST-109 oral film compared to intramuscular injection of epinephrine.”

Source: [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Multiple formulations and dose strengths evaluated in Part 1

> “In Part 1 of the EPIPHAST study, multiple oral film formulations and dosage strengths of AQST-109 were evaluated.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="topic-3.1.7.5-2"></a>

###### Intramuscular comparators used in Part 1

> “the healthy volunteers were also exposed to a 0.5mg intramuscular injection (IM) of epinephrine, allowing for a comparison with the pharmacokinetics, safety, and tolerability of the higher end of the approved dosage range of epinephrine, consistent with guidance received from the U.S. Food and Drug Administration (FDA) in a written response to the company’s pre-Investigational New Drug (pre-IND) submission.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="topic-3.1.7.5-3"></a>

###### AQST-109 12 mg versus epinephrine 0.3 mg intramuscular injection in Part 2

> “Part 2 is a randomized, crossover design comparing AQST-109 12mg to epinephrine IM 0.3mg.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Time to Maximum Epinephrine Concentration as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Time to a concentration associated with hemodynamic effect

> “The median time to reach 100 pg/mL, which has been suggested to be the threshold for the onset of hemodynamic effects, was 8 minutes for AQST-109 and 10 minutes for the 0.3mg IM injection.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="topic-3.1.7.6.1-2"></a>

###### Partial area under the curve within clinically relevant windows

> “The Area Under the Curve (AUC) within the clinically relevant periods of 10 minutes, 20 minutes, and 30 minutes, were comparable for both AQST-109 and the 0.3mg IM injection.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="topic-3.1.7.6.1-3"></a>

###### Pharmacodynamic parameters assessed

> “In addition to positive pharmacokinetic results, AQST-109 demonstrated favorable pharmacodynamic effects on systolic blood pressure, diastolic blood pressure, and heart rate.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Participants and doses in Part 2 and Part 3

> “Part 2 of the EPIPHAST study was a replicate design crossover study in twenty-four (24) healthy subjects comparing the pharmacokinetic and pharmacodynamic measures of AQST-109 12 mg and epinephrine intramuscular injection 0.3 mg.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Part 1 pharmacokinetics of two film configurations

> “As shown in the figure below, the lead formulation of AQST-109 rapidly reached clinically meaningful blood concentrations when delivered in two different physical configurations, with a median Tmax of 13.5 minutes and 22.5 minutes, respectively. Part 1 also demonstrated arithmetic mean maximum concentrations (Cmax) of 771 pg/mL and 580 pg/mL for the two configurations, or geometric mean Cmax values of 258pg/mL and 268pg/mL for the two configurations, respectively.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="topic-3.1.7.8.3-2"></a>

###### Part 2 pharmacokinetics of AQST-109 12 mg versus intramuscular epinephrine

| Study result | AQST-109 12 mg (N=48 doses) | Epinephrine IM injection 0.3 mg (N=48 doses) |
| --- | --- | --- |
| Arithmetic mean Cmax (pg/mL) | “426.1” | “396.7” |
| Geometric mean Cmax (pg/mL) | “274.3” | “350.6” |
| AUC 0-10 minutes (hr*pg/mL) | “7.9” | “9.4” |
| AUC 0-20 minutes (hr*pg/mL) | “33.1” | “23.0” |
| AUC 0-30 minutes (hr*pg/mL) | “56.7” | “47.5” |

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="topic-3.1.7.8.3-3"></a>

###### Part 2 time to maximum concentration

> “The median time to maximum concentration (Tmax) was observed to be 15 minutes for AQST-109, compared to 50 minutes for the epinephrine 0.3mg intra-muscular (IM) injection.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="topic-3.1.7.8.3-4"></a>

###### Part 3 effect of tongue hold time

> “The median time to maximum concentration (Tmax) was observed to be 12 minutes for AQST-109 compared to 50 minutes for the epinephrine 0.3mg intra-muscular (IM) injection from Part 2 of the EPIPHAST study.”

Source: [Aquestive Therapeutics EPIPHAST Part 3 initial results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000162828022017268/aqstepiphastpart3-arm1xt.htm)

<a id="topic-3.1.7.8.3-5"></a>

###### Part 3 effect of recent food intake

> “The data showed that administering the film sublingually two minutes after consuming a peanut butter sandwich had no statistical impact on the resulting pharmacokinetics when compared to previous data from the initial Part 3 dataset. The medium time to maximum concentration (Tmax) and partial area under the curve (AUC) results were comparable and the time to reach Tmax remained 12 minutes when sublingually administered after consumption of a peanut butter sandwich. The geometric mean maximum concentration, or Cmax of 286 pg/mL was also comparable to previous data from Part 3.”

Source: [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)

<a id="topic-3.1.7.8.3-6"></a>

###### Part 3 effect of swallowing the film whole with water

> “The data also showed that swallowing the film whole immediately with water unexpectedly resulted in significant absorption of epinephrine. This finding has the potential of further de-risking the development program by lowering the risks associated with patient non-compliance to the administration instructions in a real-world setting. The Cmax was 313 pg/mL and the Tmax, while slower than the sublingual administration was significantly faster than the epinephrine 0.3mg IM injection from Parts 1 and 2 of the EPIPHAST study.”

Source: [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)

<a id="topic-3.1.7.8.3-7"></a>

###### Integrated phase 1 pharmacokinetic comparison with injectable products

> “AQST-109 yielded comparable epinephrine PK and exposure to both manual intramuscular injections and epinephrine autoinjectors. The median time to maximum concentration (Tmax) for AQST-109 was 15 minutes, compared with EpiPen (10 minutes), generic EpiPen (15 minutes), Auvi-Q (30 minutes), and manual intramuscular injection (50 minutes). There was also an early, rapid, and consistent increase in systolic blood pressure, diastolic blood pressure, and heart rate after the administration of AQST-109.”

Source: [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/)

Additional sources: [Aquestive Therapeutics AAAAI poster presentations (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-present-positive-data-pharmacokinetic-and)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Tolerability in Part 1 and Part 2

> “Part 1 showed that key pharmacokinetic measures were aligned with previous favorable results for AQST-109 and that the product was well tolerated with no serious adverse events.”

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)

<a id="topic-3.1.7.8.5-2"></a>

###### Tolerability reported for Part 2

> “The results were aligned with previous positive results reported for AQST-109, and the product candidate was well tolerated with no serious adverse events.”

Source: [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary: study limitations

EPIPHAST was an open-label adaptive crossover study in healthy adult volunteers conducted in Canada, and its parts used small numbers of doses, for example 48 doses per treatment in Part 2 and 21 to 23 doses per arm in the Part 3 hold-time comparison. Comparisons between Part 3 arms and the intramuscular injection were made against data generated in Part 2 rather than within the same treatment period, and formulations and configurations changed between parts, so results are not uniform across the study. No registry record for the study was located, and the numeric results are reported in company announcements rather than a full study publication.

Source: [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm); [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2); [Aquestive Therapeutics EPIPHAST Part 3 initial results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000162828022017268/aqstepiphastpart3-arm1xt.htm); [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)

<a id="heading-3.1.8"></a>

#### 3.1.8 Anaphylm Self-administration Pharmacokinetic Study

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Comparison of participant self-administration with healthcare-provider administration

> “The single-dose, three-period, randomized crossover study design compared the PK and pharmacodynamics (PD) of Anaphylm self-administered, Anaphylm HCP administered, and Adrenalin manual intramuscular (IM) injection HCP administered.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Topline results reported in July 2024

> “07.25.24 at 8:00 AM EDT”
> “today released positive topline PK data from the self-administration study of Anaphylm™ (epinephrine) Sublingual Film.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Single-dose three-period randomized crossover design

> “The single-dose, three-period, randomized crossover study design compared the PK and pharmacodynamics (PD) of Anaphylm self-administered, Anaphylm HCP administered, and Adrenalin manual intramuscular (IM) injection HCP administered.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Healthy adult participants

> “The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at various times after dosing in 36 healthy adult subjects.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Three administration conditions

> “The single-dose, three-period, randomized crossover study design compared the PK and pharmacodynamics (PD) of Anaphylm self-administered, Anaphylm HCP administered, and Adrenalin manual intramuscular (IM) injection HCP administered.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Maximum Epinephrine Concentration and Area Under the Curve as the Primary Endpoints

<a id="topic-3.1.8.6.1-1"></a>

###### Primary pharmacokinetic parameters

> “The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at various times after dosing in 36 healthy adult subjects.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="topic-3.1.8.6.1-2"></a>

###### Baseline correction method for the reported concentrations

> “Lines on the graph above represent the geometric means of baseline-corrected epinephrine concentration across study timepoints. Baseline-corrected values were calculated by subtracting from the mean of three pre-dose concentrations measured at 60-, 30- and 15-minutes prior to treatment administration.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Participants dosed

> “The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at various times after dosing in 36 healthy adult subjects.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Pharmacokinetic comparison of self-administration and provider administration

> “There was no statistical difference between the Anaphylm self-administered and HCP-administered arms of the study. The median time to maximum concentration (Tmax) was 15 minutes for both the Anaphylm self-administered and HCP-administered arms, while the median Tmax for the Adrenalin IM HCP administered arm was 50 minutes post administration.”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="topic-3.1.8.8.3-2"></a>

###### Primary endpoints met

> “Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)”

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary: study limitations

The study enrolled 36 healthy adult volunteers who self-administered the film under supervision in a clinical setting, which does not reproduce administration during an allergic reaction. The design was open label with an intramuscular comparator given by a healthcare provider, and only median Tmax values and a qualitative statement of no statistical difference between the self-administered and provider-administered arms have been released; Cmax, area under the curve values, confidence intervals, and safety results were not reported. No registry record or peer-reviewed publication of the study was located.

Source: [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)

<a id="heading-3.1.9"></a>

#### 3.1.9 Anaphylm Temperature and pH Pharmacokinetic Study

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Effect of oral cavity temperature and pH on absorption

> “The single-dose, five-period, randomized crossover study was designed to compare the PK and pharmacodynamics (PD) of Anaphylm just after consuming normal water (hot, cold, and room temperature), lemon water, and baking soda water.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Topline results reported in June 2024

> “06.25.24 at 8:00 AM EDT”
> “today released positive topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm™ (epinephrine) Sublingual Film.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Single-dose five-period randomized crossover design

> “The single-dose, five-period, randomized crossover study was designed to compare the PK and pharmacodynamics (PD) of Anaphylm just after consuming normal water (hot, cold, and room temperature), lemon water, and baking soda water.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Healthy adult participants

> “The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at various times after dosing, in 30 healthy adult subjects.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Beverage conditions tested before dosing

> “The single-dose, five-period, randomized crossover study was designed to compare the PK and pharmacodynamics (PD) of Anaphylm just after consuming normal water (hot, cold, and room temperature), lemon water, and baking soda water.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Maximum Epinephrine Concentration and Area Under the Curve as the Primary Endpoints

<a id="topic-3.1.9.6.1-1"></a>

###### Primary pharmacokinetic parameters and comparison to room temperature water

> “The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at various times after dosing, in 30 healthy adult subjects.”
> “The table below provides the ratio of Cmax and AUC 0-60min following administration of Anaphylm under various test states when compared to room temperature water.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Participants dosed

> “The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at various times after dosing, in 30 healthy adult subjects.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Exposure ratios by test condition relative to room temperature water

| Test condition | Cmax ratio to room temperature water | AUC 0-60min ratio to room temperature water |
| --- | --- | --- |
| Cold water | “106%” | “98%” |
| Hot water | “104%” | “107%” |
| Lemon water (target pH: 3) | “98%” | “99%” |
| Baking soda water (target pH: 8) | “123%” | “132%” |

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="topic-3.1.9.8.3-2"></a>

###### Statistical interpretation of the exposure differences

> “Topline PK data from the study showed no statistically significant difference in PK results based on changes in temperature and pH. The most consumed beverages, such as soda, milk, coffee, and juice, have acidity between lemon water and normal water. While not statistically significant, alkaline substances like baking soda showed a somewhat higher absorption level than room-temperature water.”

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary: study limitations

The study enrolled 30 healthy adult volunteers and tested only water at three temperatures, lemon water and baking soda water, so it does not directly address the beverages and foods that the company noted fall between these acidity extremes. Pharmacodynamic results were not available at the time of the topline release, safety results were not reported, and only ratios relative to room temperature water were published, without absolute Cmax or area under the curve values or confidence intervals. No registry record or peer-reviewed publication of the study was located.

Source: [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)

<a id="heading-3.1.10"></a>

#### 3.1.10 AQST-109 First-in-human Phase 1 Single-ascending-dose Study

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Safety, tolerability, pharmacokinetic, and pharmacodynamic profiling of four formulations

> “The Phase 1 randomized, single-ascending dose (SAD) study was performed with AQST-109 in order to assess safety, tolerability, PK, and PD profiles.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Conducted in Canada with topline results reported in October 2021

> “10.25.21 at 8:31 AM EDT”
> “The study was conducted in Canada pursuant to a clinical trial application approved by Health Canada.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Randomized single-ascending-dose design across four formulations

> “Subjects participating in the trial received, in ascending fashion, sublingually administered doses of AQST-109 across four different formulations. The four formulation compositions were varied to assess critical absorption factors including drug loading and the use of inventive excipients designed to influence absorption, stability, and the conversion of the prodrug.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Healthy volunteers

> “The changes observed suggest a comparable effect for AQST-109 when compared to autoinjectors in healthy volunteers.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Dose strengths of the target formulation

> “In addition, the target formulation had similar median Tmax values at lower dose strengths (15 minutes and 17.5 minutes for the 6 mg and 9 mg doses, respectively, included in the study).”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Maximum Epinephrine Concentration and Time to Maximum Concentration as the Primary Endpoints

<a id="topic-3.1.10.6.1-1"></a>

###### Comparability measures chosen against approved autoinjectors

> “Key clinical measures for comparability to existing autoinjectors (Cmax, Tmax, and area under the curve, or AUC) were within expected ranges for formulations 1, 2 (target), and 4”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="topic-3.1.10.6.1-2"></a>

###### Pharmacodynamic markers measured

> “The PD markers measured changes from baseline in heart rate, systolic blood pressure, and diastolic blood pressure.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Doses administered per formulation

| Film formulation | Dosings (n) |
| --- | --- |
| 1 | “6” |
| 2 (target) | “8” |
| 3 | “6” |
| 4 | “7” |

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Pharmacokinetics of the target formulation

> “This study indicated that AQST-109 was absorbed and rapidly converted to epinephrine with an observed median Tmax of 15 minutes and an observed geometric mean Cmax of 762 pg/mL for the target formulation.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="topic-3.1.10.8.3-2"></a>

###### Pharmacokinetic parameters across the four formulations

| Parameter | Formulation 1 | Formulation 2 (target) | Formulation 3 | Formulation 4 |
| --- | --- | --- | --- | --- |
| Cmax (pg/mL) | “552” | “762” | “164” | “307” |
| AUC 0-t (hr*pg/mL) | “634” | “603” | “329” | “303” |
| Median Tmax (minutes) | “15” | “15” | “20” | “10” |
| Tmax range (minutes) | “15-25” | “10-35” | “20-50” | “5-50” |

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="topic-3.1.10.8.3-3"></a>

###### Pharmacodynamic comparability with autoinjectors

> “Observed PD values were comparable to existing data for autoinjectors”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

###### Treatment-emergent adverse events and absence of serious adverse events

> “Safety data indicated that AQST-109 was generally well tolerated with no serious adverse events (SAE’s), significant medical events, or treatment-related severe adverse events reported within the trial. All treatment-emergent adverse events (TEAEs) deemed at least possibly related were mild to moderate in nature across cohorts.”

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary: study limitations

The study was a first-in-human single-ascending-dose evaluation in healthy volunteers with 6 to 8 dosings per formulation, so estimates of Cmax, Tmax, and area under the curve rest on very small numbers. It included no randomized injectable comparator arm; comparisons with EpiPen and Auvi-Q were drawn from previous and published studies rather than measured in the same participants. Two of the four formulations, including the formulation later taken forward, differed from the final commercial configuration, and no registry record or peer-reviewed publication of this individual study was located.

Source: [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)

## Related pages
- [Anaphylm (dibutepinephrine): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Terms and abbreviations](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations.md)
- [Anaphylm (dibutepinephrine): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/executive-summary.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Product information and disease description](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Economic information and modeling report](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economics) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economics.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: References](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/references) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/references.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: prevalence by geography](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/prevalence) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/prevalence.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/cost-effectiveness-analyses.md)
